Search
Search Funnelback University
- Refined by:
- Date: 2022
Your query has been expanded to news |u:www.enterprize.cam.ac.uk. Search for news |u:www.enterprise.cam.ac.uk instead.
31 -
80 of
183
search results for news |u:www.enterprise.cam.ac.uk or news |u:www.enterprize.cam.ac.uk
Fully-matching results
-
Science and Technology Facilities Council (STFC) Knowledge Exchange…
https://www.enterprise.cam.ac.uk/grant/science-and-technology-facilities-council-stfc-knowledge-exchange-and-commercialisation-kec-fellowships/18 Jan 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. Science and Technology Facilities Council (STFC) Knowledge Exchange and Commercialisation (KEC) Fellowships. The KEC Fellowship scheme is designed to facilitate the development of -
DIOSynVax: tackling COVID-19 – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/diosynvax-tackling-covid-19/11 Apr 2022: Historically, the creation of an effective new vaccine has required years of work and hundreds of millions of pounds. -
CAM2 software for hearing aid fitting – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/reagents/cam2-software-for-hearing-aid-fitting/9 May 2022: CAM2 has been developed to provide a superior solution for the tailoring of wide-band hearing aid parameters using the audiogram alone, and is an essential new tool in the audiology -
New Head at Cambridge Enterprise Seed Funds | University of Cambridge
https://www.enterprise.cam.ac.uk/news/new-head-at-cambridge-enterprise-seed-funds/7 Apr 2022: Search. Search. New Head at Cambridge Enterprise Seed Funds. News. New Head at Cambridge Enterprise Seed Funds.. ... This news story was first published on Cambridge Enterprise's website on 06 April 2022. -
Research tools licensing – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/for-the-university/develop-a-commercial-opportunity/research-tools/19 Dec 2022: We have been licensing research tools for over a decade and can therefore fully support you through the process. -
Impact Insight: Xampla – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/video/impact-insight-xampla/12 May 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. Impact Insight: Xampla. Share:. Impact Insight video case study: Xampla. The first in our series of Impact Insight videos focuses on Xampla. It tells the exciting story of the research -
Impact Ideation Workshop: Global Sustainable Development Monday 28th…
https://www.enterprise.cam.ac.uk/wp-content/uploads/2022/12/2022.11.23_AHSS-QA-Maryam-Tanwir_Web.pdf2 Dec 2022: But unfortunately the minute that there was a change in government, the new government cut off all funding and the project was in disarray. -
Impact Insight video case study: Xampla – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/impact-insight-video-case-study-xampla/15 Mar 2022: The first in our new series of Impact Insight videos focuses on Xampla. ... Whether you’re a University researcher or academic with a novel idea or technology, an investor keen to support innovations emerging from the University, or an external -
KARPAS 25 Human Myeloma cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-25-human-myeloma-cell-line/9 May 2022: KARPAS 25 Human Myeloma cell line useful in oncology research, developed at the University of Cambridge. -
The Carbon Challenge: Daily Decarbonisation – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/news/carbon-challenge-2022/28 Jan 2022: For news on upcoming Carbon Challenge events and how to register, visit our Events pages. -
Creative Cambridge 2022 highlights – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/video/creative-cambridge-2022-highlights/18 Aug 2022: With themes of Content, Collections and Community, Creative Impact, and Creative Innovation, the day featured great speakers, inspirational panels, demos, pitches and of course conversation designed to spark new ideas and ... More on Creative Cambridge. -
KARPAS 417 Human Myeloma cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-417-human-myeloma-cell-line/9 May 2022: KARPAS 417 Human Myeloma cell line useful in oncology research, developed at the University of Cambridge. -
Impact Insight video case study: Versed AI – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/impact-insight-video-case-study-versed-ai/15 Mar 2022: Impact Insight video case study: Versed AI. The second in our new series of Impact Insight videos focuses on Versed AI. ... Whether you’re a University researcher or academic with a novel idea or technology, an investor keen to support innovations -
Realising the market potential of software – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/for-the-university/develop-a-commercial-opportunity/realising-the-market-potential-of-software/18 Jul 2022: Related news and case studies. Pause. Play. Review our answers to your most frequently asked questions. -
New grafting technique published in Nature - Cambridge Enterprise
https://www.enterprise.cam.ac.uk/news/research-supported-by-cambridge-enterprise-and-ceres-agri-tech-published-in-nature/16 Mar 2022: Share:. New grafting technique could combat the disease threatening Cavendish bananas. ... Grafting genetically different root and shoot tissues can result in a plant with new traits – ranging from dwarf shoots, to pest and disease resistance. -
Impact Insight: Versed AI – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/video/impact-insight-versed-ai/12 May 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. Impact Insight: Versed AI. Share:. Impact Insight video case study: Versed AI. The second in our Impact Insight video series focuses on Versed AI. It tells the story behind the creation -
Research Report Commercialisation and Policy Research Authors: Dr…
https://www.enterprise.cam.ac.uk/wp-content/uploads/2022/12/Roundtable-report_Commercialisation_PolicyResearch.pdf15 Dec 2022: Market-based solutions comprise many arrangements, such as licensing innovative tools, creating new companies (including social ventures), carrying out consultancies, and bringing. ... The above reduces the possibilities that usually originate from -
KARPAS 929 Human Myeloma cell line - Cambridge Enterprise
https://www.enterprise.cam.ac.uk/reagents/karpas-929-human-myeloma-cell-line/9 May 2022: KARPAS 929 Human Myeloma cell line, developed at the University of Cambridge, useful in oncology research. -
Impact Insight video case study: iKVA – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/impact-insight-video-case-study-ikva/23 Mar 2022: Whether you’re a University researcher or academic with a novel idea or technology, an investor keen to support innovations emerging from the University, or an external organisation looking for new -
Watch our #nextgreatidea film – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/video/watch-our-nextgreatidea-film/15 Feb 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. Watch our #nextgreatidea film. Share:. Our film is a distinctive take on innovation that showcases some of the world-changing ideas we have supported in the journey to market – from a -
The journey of a University idea – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/for-the-university/develop-a-commercial-opportunity/the-journey-of-a-university-idea/10 May 2022: Here are some ideas:. Performance/applications data. Prototype development, scale-up of process, develop new applications. ... parties. Example of a benefit statement. We can help primary school teachers teach children to speak a new language more -
£1.5m seed funding for Cambridge spin-out iKVA – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/news/university-of-cambridge-spin-out-ikva-secures-1-5m-seed-funding/2 Feb 2022: £1.5m investment via Crowdcube and Cambridge Enterprise creates new jobs and further development of the tech. -
KARPAS 707H Human Myeloma cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-707h-human-myeloma-cell-line/9 May 2022: KARPAS 707H Human myeloma cell line suitable for the generation of stable human hybridomas for the creation of fully human monoclonal antibodies. -
Nyobolt: Supercharging the electric revolution – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/nyobolt-supercharging-the-electric-revolution/11 Apr 2022: A new class of battery technology. Nyobolt’s team of experts has pioneered a new class of battery technology that achieves record-breaking ultra-fast charging. -
Cambridge Enterprise 1 Cambridge Enterprise: Q&A w ith Joao ...
https://www.enterprise.cam.ac.uk/wp-content/uploads/2022/11/2022.11.23_AHSS-QA-Joao-Costa_Web-1.pdf23 Nov 2022: a foothold on the ground, who could go in and do preliminary consultations to grasp whether the communities could be interested or not in trying something new. -
Cambridge recognised for its leadership in knowledge exchange –…
https://www.enterprise.cam.ac.uk/news/cambridge-recognised-for-its-leadership-in-knowledge-exchange/27 Sep 2022: Early stage innovations are licensed to existing companies for development or spun out as new companies. ... Among these were three companies developing new technologies focused on reducing carbon emissions—and Carbon Re. -
KARPAS 1272 Human Myeloma cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-1272-human-myeloma-cell-line/9 May 2022: KARPAS 1272 Human Myeloma cell line, useful in oncology research, developed at the University of Cambridge. -
Sustainability, investment and the Carbon Challenge – Cambridge…
https://www.enterprise.cam.ac.uk/video/sustainability-investment-and-the-carbon-challenge/12 Oct 2022: Chris Gibbs shares his perspectives on the importance of sustainability, investing in sustainability businesses and building entrepreneurial mindsets through the Carbon Challenge. -
Impact Insight video case study: Kalamna toolkit – Cambridge…
https://www.enterprise.cam.ac.uk/case-studies/impact-insight-video-case-study-kalamna-toolkit/15 Mar 2022: Impact Insight video case study: Kalamna toolkit. The third in our new series of Impact Insight videos focuses on the licensing of the Kalamna toolkit for learning Arabic. ... Dr Khalil has spent her career researching how young Arabic learners can be -
TenU receives £4 million to boost research commercialisation –…
https://www.enterprise.cam.ac.uk/news/tenu-receives-4-million-to-boost-research-commercialisation/18 Aug 2022: with the potential to provide tens of thousands of new jobs over the next few years. -
KARPAS 241 Human Monoblastic cell line
https://www.enterprise.cam.ac.uk/reagents/karpas-241-human-monoblastic-cell-line/9 May 2022: KARPAS 241 Human Monoblastic cell line useful in oncology research, developed at the University of Cambridge. -
Ceres Agri-Tech Partnership – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/ceres-a-rich-harvest-of-agri-tech-projects/11 Apr 2022: Over the past year, the team has identified and reviewed 55 new opportunities and presented 13 to the Ceres Investment Committee. -
COBRAS Concrete Bridge Assessment Program – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/reagents/cobras-concrete-bridge-assessment-program/9 May 2022: COBRAS Concrete Bridge Assessment Program is a yield-line analysis software for assessing the ultimate load capacity of concrete structures. -
Cambridge joins $72.5m round launching mitochondrial therapies…
https://www.enterprise.cam.ac.uk/news/cambridge-joins-72-5m-round-launching-mitochondrial-therapies-pioneer-pretzel/19 Sep 2022: We are excited to pioneer a new era in the treatment of diseases related to mitochondrial dysfunction. ... The expertise we have assembled and the platform technologies we have created will allow new inroads into treating both rare genetic diseases as -
BOADICEA: Calculating the risk of breast cancer – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/boadicea-calculating-the-risk-of-breast-cancer/11 Apr 2022: New Zealand Family Cancer Services. BOADICEA being incorporated within BRRISK helps time-poor GP’s to stratify patients according to risk. ... Oncoplastic Breast Surgeon, Auckland, New Zealand. Pause. Play. If you would like more information on BOADICEA -
Brief Early Skills & Support Index (BESSI) – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/reagents/brief-early-skills-support-index-bessi/9 May 2022: Questionnaire developed at the University of Cambridge and validated for use with reception- and nursery-aged children. -
Finalists announced in 2022 Chris Abell Postdoc Business Plan…
https://www.enterprise.cam.ac.uk/news/finalists-announced-in-2022-chris-abell-postdoc-business-plan-competition/4 Oct 2022: The finalists’ pitches will be judged on a number of criteria, including each business’s competitive position, the potential for new business creation, and each team’s collective skill set. -
Case study: Futures We Want – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/consultancy-services-determining-the-futures-we-want/11 Apr 2022: Evidence included scientific papers, government reports, and local news articles. The close collaboration with local expert teams throughout the process brought great depth of knowledge, and ensured that visions remained focused -
Human CD59 monoclonal antibody YTH 53.1
https://www.enterprise.cam.ac.uk/reagents/human-cd59-monoclonal-antibody-yth-53-1/9 May 2022: Hybridoma cell line producing YTH 53.1 antibodies raised against human CD59 which are rat monoclonal antibodies of the IgG2b isotype. -
Sparxell wins the 2022 Chris Abell Postdoc Business Plan Competition…
https://www.enterprise.cam.ac.uk/news/sparxell-wins-the-2022-chris-abell-postdoc-business-plan-competition/11 Nov 2022: Mobile menu. Mobile menu. Search. back. back. back. back. back. 11 November 2022. Sparxell wins the 2022 Chris Abell Postdoc Business Plan Competition. Share:. Sparxell has won the Chris Abell Postdoc Business Plan Competition 2022, securing the £20 -
Human CD7 monoclonal antibody YTH 30.15
https://www.enterprise.cam.ac.uk/reagents/human-cd7-monoclonal-antibody-yth-30-15/9 May 2022: Hybridoma cell line producing YTH 30.15 antibodies raised against human CD7 which are rat monoclonal antibodies of the IgG2b isotype. -
HappyShield: A simple, elegant solution to PPE scarcity – Cambridge…
https://www.enterprise.cam.ac.uk/case-studies/happyshield-a-simple-elegant-solution-to-ppe-scarcity/11 Apr 2022: HappyShield provides a barrier from splashes and sprays of infected bodily fluids and can be cleaned and reused indefinitely. -
Semi-finalists announced in 2022 Chris Abell Postdoc Business Plan…
https://www.enterprise.cam.ac.uk/news/semi-finalists-announced-in-2022-chris-abell-postdoc-business-plan-competition/17 Aug 2022: In addition, applicants will benefit from even more support with our new summer programme, which offers an additional series of activities through a blend of round table discussions, one-to-one -
Rat CD45 monoclonal antibody YTH 24.5
https://www.enterprise.cam.ac.uk/reagents/human-cd45-monoclonal-antibody-yth-24-5/9 May 2022: Hybridoma cell line producing YTH 24.5 antibodies raised against human CD45 which are rat monoclonal antibodies of the IgG2b isotype. -
Apollo Therapeutics: Pioneering collaboration launches its next phase …
https://www.enterprise.cam.ac.uk/case-studies/apollo-therapeutics-pioneering-collaboration-launches-its-next-phase/11 Apr 2022: so-called Valley of Death, the interval when promising new research can wither and die for lack of funding. ... Next steps. Apollo is now advancing into clinical development as well as identifying new programmes. -
Human CD11a monoclonal antibody YTH 81.5
https://www.enterprise.cam.ac.uk/reagents/human-cd11a-monoclonal-antibody-yth-81-5/9 May 2022: Hybridoma cell line producing YTH 81.5 antibodies raised against human CD11a which are rat monoclonal antibodies of the IgG2a isotype. -
Human CD16 monoclonal antibody YFC 120.5
https://www.enterprise.cam.ac.uk/reagents/human-cd16-monoclonal-antibody-yfc-120-5/9 May 2022: Hybridoma cell line producing YFC 120.5 antibodies raised against human CD16 which are rat monoclonal antibodies of the IgG2b isotype. -
Cambridge spin-out raises $6m seed round for transformative…
https://www.enterprise.cam.ac.uk/news/cambridge-spin-out-raises-6m-seed-round-for-transformative-regulatory-data-structures/12 Apr 2022: University of Cambridge spin-out RegGenome announces the completion of a $6 million seed funding round. -
Knowledge exchange in southern Africa – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/case-studies/knowledge-exchange-teaching-and-learning-in-southern-africa/11 Apr 2022: We ran a knowledge exchange programme on research commercialisation for three southern African universities in 2019. -
FcgRlla 131R receptor expressing cell line
https://www.enterprise.cam.ac.uk/reagents/fcgrlla-131r-receptor-expressing-cell-line/9 May 2022: CHO cells transfected to express human FcgRlla allotype 131R as a transmembrane protein with its native intracellular domain.
Search history
Recently clicked results
Recently clicked results
Your click history is empty.
Recent searches
Recent searches
Your search history is empty.